Pfizer (PFE) Price to Sales (2009 - 2026)

Pfizer (PFE) has reported Price to Sales for 18 consecutive years, with 9.21 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales fell 1.89% year-over-year to 9.21 in Q2 2026; TTM through Jun 2026 was 2.17, a 38.31% increase from a year earlier, with the FY2025 full-year figure at 2.26, down 4.25% from the prior year.
• Price to Sales was 9.21 for Q2 2026 at Pfizer, down from 10.66 in the prior quarter.
• Over five years, Price to Sales peaked at 88.29 in Q4 2022 and troughed at 3.59 in Q3 2024.
• A 5-year average of 17.86 and a median of 10.58 in 2022 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales slumped 46.38% in 2023 and surged 125.68% in 2025, its largest moves.
• Over 5 years, Price to Sales stood at 88.29 in 2022, then sank by 46.38% to 47.34 in 2023, then plunged by 92.41% to 3.59 in 2024, then jumped by 124.36% to 8.06 in 2025, then advanced by 14.19% to 9.21 in 2026.
• The last three Price to Sales figures came in at 9.21 (Q2 2026), 10.66 (Q1 2026), and 8.06 (Q4 2025), per Business Quant data.